Real-world Efficacy and Safety of Immune check point inhibitors for Refractory Head and Neck Cancer: A Retrospective Multicenter Study
Not Applicable
Recruiting
- Conditions
- Neoplasms
- Registration Number
- KCT0004258
- Lead Sponsor
- Chung-Ang Univerisity Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
? Patients with larynx, oral cavity, oropharynx, nasal cavity, maxillary sinus, hypopharyngeal carcinoma confirmed histologically as squamous cell carcinoma
? Patients who have undergone palliative chemotherapy for relapse after surgery or initial metastasis
? Patients who have received immune checkpoint inhibitors
Exclusion Criteria
? Nasopharyngeal cancer patients
? Patients who have not been observed after a single dose of immune checkpoint inhibitors (follow-up loss) are difficult to confirm the effects or adverse events
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Objective response rate
- Secondary Outcome Measures
Name Time Method Progression Free Survival;Duration of response;Overall Survival;Incidence of Hyperprogression;Incidence of Immune related adverse events